RELAPSE MULTIPLE MYELOMA

This study is testing a new type of personalized cell therapy for people with multiple myeloma that has come back or stopped responding to other treatments. Doctors will collect and modify a patient's own immune cells (T-cells) to recognize and attack two specific targets on the …

This study is testing whether a combination of four drugs is safe and effective for people with multiple myeloma that has returned or stopped responding to standard treatments, including CAR-T cell therapy. About 83 adults whose cancer worsened after at least two prior treatment …

This early-stage study is testing whether a personalized cancer vaccine, made from a patient's own tumor and immune cells, is safe and works well when given alongside an approved drug called elranatamab. The goal is to see if this combination can better control multiple myeloma i…

This study is testing whether the drug elranatamab can help prevent multiple myeloma from returning or worsening in patients who have already received a specialized CAR-T cell therapy called idecabtagene vicleucel. The research involves about 32 adults with relapsed or hard-to-tr…

This study is testing whether using a drug called talquetamab before a personalized cell therapy (cilta-cel) is safe and feasible for people with multiple myeloma that has returned or stopped responding to treatment. The research will enroll 31 adults who have already tried at le…

This study aims to find the best way to prevent taste changes (dysgeusia) that can occur when taking the myeloma drug talquetamab. About 130 adults with relapsed or hard-to-treat multiple myeloma will try different preventive treatments. Researchers will carefully measure taste c…